Levetiracetam in children with refractory epilepsy: Lack of correlation between plasma concentration and efficacy

Seizure

Volumn 18, Issue 8, 2009, Pages 559-563

  Giroux, Patricia C ^a,b   Salas Prato, Milagros ^b   Théorêt, Yves ^b   Carmant, Lionel ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Children; Efficacy; Epilepsy; Levetiracetam; Safety; Therapeutic monitoring

Indexed keywords

ETIRACETAM;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT; CHILD; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REFRACTORY PERIOD; SCHOOL CHILD; SEIZURE SUSCEPTIBILITY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; ANTICONVULSANTS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPILEPSY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PIRACETAM; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 69749123287     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2009.05.007     Document Type: Article

References (33)

1. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology & Therapeutics 85 2 (2000) 77-85
2. Gillard M., Chatelain P., and Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. European Journal of Pharmacology 536 1-2 (2006) 102-108
3. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 101 26 (2004) 9861-9866
4. Pisani A., Bonsi P., Martella G., De Persis C., Costa C., Pisani F., et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 45 7 (2004) 719-728
5. Klitgaard H., Matagne A., Gobert J., and Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology 353 (1998) 191-206
6. Margineanu D.G., and Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. European Journal of Pharmacology 466 3 (2003) 255-261
7. Coppola G., Mangano S., Tortorella G., Pelliccia A., Fels A., Romano A., et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Research 59 1 (2004) 35-42
8. Grosso S., Franzoni E., Coppola G., Iannetti P., Verrotti A., Cordelli D.M., et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 14 4 (2005) 248-253
9. Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 46 Suppl. 9 (2005) 154-160
10. Herranz J.L., Prats-Viñas J.M., Campistol J., Campos-Castelló J., Rufo-Campos M., Casas-Fernández C., et al. Effectiveness and safety of levetiracetam in 133 children with medication resistant epileptic seizures. Revista de Neurologia 43 7 (2006) 393-397
11. Koukkari M.W., and Guarino E.J. Retrospective study of the use of levetiracetam in childhood seizure disorders. Journal of Child Neurology 19 12 (2004) 944-947
12. Lagae L., Buyse G., Deconinck A., and Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. European Journal of Paediatric Neurology 7 3 (2003) 123-128
13. Lagae L., Buyse G., and Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 14 1 (2005) 66-71
14. Neuwirth M., Saracz J., Hegyi M., Paraicz E., Kollár K., Móser J., et al. Experience with levetiracetam in childhood epilepsy. Ideggyógyászati szemle 59 5-6 (2006) 179-182
15. Martens-Lobenhoffer J., and Bode-Böger S.M. Determination of levetiracetam in human plasma with minimal sample pretreatment. Journal of Chromatography 819 1 (2005) 197-200
16. Coppola G., Franzoni E., Verrotti A., Garone C., Sarajlija J., Operto F.F., et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain & Development (2006) [Epub ahead of print]
17. Verrotti A., Coppola G., Manco R., Ciambra G., Iannetti P., Grosso S., et al. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures. Seizure 16 3 (2007) 271-275
18. von Stuelpnagel C., Holthausen H., and Kluger G. Long-term use of levetiracetam in patients with severe childhood-onset epilepsy. European Journal of Paediatric Neurology 11 6 (2007) 341-345
19. Khurana D.S., Kothare S.V., Valencia I., Melvin J.J., and Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatric Neurology 36 (2007) 227-230
20. Lambrechts D.A., Sadzot B., van Paesschen W., van Leusden J.A., Carpay J., Bourgeois P., et al. Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands. Seizure 15 6 (2006) 434-442
21. Mandelbaum D.E., Bunch M., Kugler S.L., Venkatasubramanian A., and Wollack J.B. Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use. Journal of Child Neurology 20 7 (2005) 590-594
22. Losher W., and Honack D. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia 41 12 (2000) 1499-1506
23. Grosso S., Cordelli D.M., Franzoni E., Coppola G., Capovilla G., Zamponi N., et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure 16 (2007) 345-350
24. De Los Reyes E.C., Sharp G.B., Williams J.P., and Hale S.E. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatric Neurology 30 4 (2004) 254-256
25. Gümüş H., Kumandaş S., and Per H. Levetiracetam monotherapy in newly diagnosed cryptogenic West syndrome. Pediatric Neurology 37 5 (2007) 350-353
26. Kelly K., Stephen L.J., and Brodie M.J. Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy & Behavior 5 6 (2004) 878-883
27. Opp J., Tuxhorn I., May T., Kluger G., Wiemer-Kruel A., Kurlemann G., et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 14 7 (2005) 476-484
28. Sirsi D., and Safdieh J.E. The safety of levetiracetam. Expert Opinion on Drug Safety 6 3 (2007) 241-250
29. Bauer J., Ben-Menachem E., Krämer G., Fryze W., Da Silva S., and Kasteleijn-Nolst Trenité D.G. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurologica Scandinavica 114 3 (2006) 169-176
30. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 5 (2002) 518-524
31. May T.W., Rambeck B., and Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Therapeutic Drug Monitoring 25 6 (2003) 690-699
32. Mecarelli O., Li Voti P., Pro S., Romolo F.S., Rotolo M., Pulitano P., et al. Saliva and serum levetiracetam concentrations in patients with epilepsy. Therapeutic Drug Monitoring 29 3 (2007) 313-318
33. Lancelin F., Franchon E., Kraoul L., Garciau I., Brovedani S., Tabaouti K., et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Therapeutic Drug Monitoring 29 5 (2007) 576-583